Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.

Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE.

Bone Marrow Transplant. 2017 Apr;52(4):580-587. doi: 10.1038/bmt.2016.322. Epub 2016 Dec 19.

2.

Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.

Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1792-1800. doi: 10.1016/j.bbmt.2016.06.023. Epub 2016 Jul 1.

3.

Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children.

Liao GP, Harting MT, Hetz RA, Walker PA, Shah SK, Corkins CJ, Hughes TG, Jimenez F, Kosmach SC, Day MC, Tsao K, Lee DA, Worth LL, Baumgartner JE, Cox CS Jr.

Pediatr Crit Care Med. 2015 Mar;16(3):245-55. doi: 10.1097/PCC.0000000000000324.

4.

Exploring the Cancer Experiences of Young Adults in the Context of Stem Cell Transplantation.

Brassil KJ, Engebretson JC, Armstrong TS, Segovia JH, Worth LL, Summers BL.

Cancer Nurs. 2015 Jul-Aug;38(4):260-9. doi: 10.1097/NCC.0000000000000200.

5.

Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia.

Poon LM, Bassett R Jr, Rondon G, Hamdi A, Qazilbash M, Hosing C, Jones RB, Shpall EJ, Popat UR, Nieto Y, Worth LL, Cooper L, De Lima M, Champlin RE, Kebriaei P.

Bone Marrow Transplant. 2013 May;48(5):666-70. doi: 10.1038/bmt.2012.195. Epub 2012 Oct 22.

PMID:
23085830
6.

Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.

Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M.

Leuk Lymphoma. 2012 May;53(5):901-6. doi: 10.3109/10428194.2011.631159. Epub 2012 Jan 3.

7.

Autologous bone marrow mononuclear cell therapy for severe traumatic brain injury in children.

Cox CS Jr, Baumgartner JE, Harting MT, Worth LL, Walker PA, Shah SK, Ewing-Cobbs L, Hasan KM, Day MC, Lee D, Jimenez F, Gee A.

Neurosurgery. 2011 Mar;68(3):588-600. doi: 10.1227/NEU.0b013e318207734c.

PMID:
21192274
8.

Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.

Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE.

Biol Blood Marrow Transplant. 2011 Jun;17(6):893-900. doi: 10.1016/j.bbmt.2010.09.022. Epub 2010 Oct 11.

9.

Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia.

Anderlini P, Acholonu SA, Okoroji GJ, Bassett RE, Shpall EJ, Qazilbash MH, Popat UR, Worth LL, Giralt SA, Champlin RE.

Leuk Lymphoma. 2011 Jan;52(1):137-41. doi: 10.3109/10428194.2010.524328. Epub 2010 Oct 12. No abstract available.

10.

Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.

Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski J.

Bone Marrow Transplant. 2010 Mar;45(3):429-36. doi: 10.1038/bmt.2009.189. Epub 2009 Aug 10.

11.

Cell therapies for traumatic brain injury.

Harting MT, Baumgartner JE, Worth LL, Ewing-Cobbs L, Gee AP, Day MC, Cox CS Jr.

Neurosurg Focus. 2008;24(3-4):E18. doi: 10.3171/FOC/2008/24/3-4/E17. Review.

12.

Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005.

Safdar A, Rodriguez GH, De Lima MJ, Petropoulos D, Chemaly RF, Worth LL, Shpall EJ, Rolston KV, Raad II, Chan KW, Champlin RE.

Medicine (Baltimore). 2007 Nov;86(6):324-33.

13.

Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.

Gordon N, Koshkina NV, Jia SF, Khanna C, Mendoza A, Worth LL, Kleinerman ES.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4503-10.

14.
15.

Interferon-alpha after autologous stem cell transplantation in pediatric patients with advanced Hodgkin's lymphoma.

Petropoulos D, Worth LL, Mullen CA, Lockhart S, Choroszy M, Chan KW.

Bone Marrow Transplant. 2006 Sep;38(5):345-9.

PMID:
16915224
16.

Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma.

Jia SF, Duan X, Worth LL, Guan H, Kleinerman ES.

Cancer Gene Ther. 2006 Oct;13(10):948-57. Epub 2006 Jun 9.

PMID:
16763609
17.

Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature.

Lee TH, Bolontrade MF, Worth LL, Guan H, Ellis LM, Kleinerman ES.

Int J Cancer. 2006 Aug 15;119(4):839-46.

18.

Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.

Petropoulos D, Worth LL, Mullen CA, Madden R, Mahajan A, Choroszy M, Ha CS, Champlin RC, Chan KW.

Bone Marrow Transplant. 2006 Mar;37(5):463-7.

PMID:
16435013
19.

Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity.

Zhou Z, Lafleur EA, Koshkina NV, Worth LL, Lester MS, Kleinerman ES.

Mol Cancer Res. 2005 Dec;3(12):685-91.

20.

Increased Fas expression reduces the metastatic potential of human osteosarcoma cells.

Lafleur EA, Koshkina NV, Stewart J, Jia SF, Worth LL, Duan X, Kleinerman ES.

Clin Cancer Res. 2004 Dec 1;10(23):8114-9.

21.

Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases.

Jia SF, Worth LL, Densmore CL, Xu B, Duan X, Kleinerman ES.

Clin Cancer Res. 2003 Aug 15;9(9):3462-8.

23.

Lorazepam for seizure prophylaxis during high-dose busulfan administration.

Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H, Slopis J.

Bone Marrow Transplant. 2002 Jun;29(12):963-5.

24.

Fas expression inversely correlates with metastatic potential in osteosarcoma cells.

Worth LL, Lafleur EA, Jia SF, Kleinerman ES.

Oncol Rep. 2002 Jul-Aug;9(4):823-7.

PMID:
12066216
25.

Eradication of osteosarcoma lung metastasis using intranasal gemcitabine.

Jia SF, Worth LL, Turan M, Duan Xp XP, Kleinerman ES.

Anticancer Drugs. 2002 Feb;13(2):155-61.

PMID:
11901308
26.

Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector.

Jia SF, Worth LL, Densmore CL, Xu B, Zhou Z, Kleinerman ES.

Cancer Gene Ther. 2002 Mar;9(3):260-6.

27.

Human bone marrow transplant rejection is associated with telomere cleavage.

Multani AS, Worth LL, Jeha S, Chan KW, Pathak S.

Int J Mol Med. 2001 Dec;8(6):607-10.

PMID:
11712073
28.

Biologic response modifiers in pediatric cancer.

Worth LL, Jeha SS, Kleinerman ES.

Hematol Oncol Clin North Am. 2001 Aug;15(4):723-40, ix. Review.

PMID:
11676281
29.

Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes.

Densmore CL, Kleinerman ES, Gautam A, Jia SF, Xu B, Worth LL, Waldrep JC, Fung YK, T'Ang A, Knight V.

Cancer Gene Ther. 2001 Sep;8(9):619-27.

30.

Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells.

Lafleur EA, Jia SF, Worth LL, Zhou Z, Owen-Schaub LB, Kleinerman ES.

Cancer Res. 2001 May 15;61(10):4066-71.

31.

A fludarabine-based conditioning regimen for severe aplastic anemia.

Chan KW, Li CK, Worth LL, Chik KW, Jeha S, Shing MK, Yuen PM.

Bone Marrow Transplant. 2001 Jan;27(2):125-8.

32.

Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.

Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, Choroszy M, Danielson M, Przepiorka D, Chan KW.

Bone Marrow Transplant. 2000 Sep;26(5):463-70.

33.
34.

9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice.

Koshkina NV, Kleinerman ES, Waidrep C, Jia SF, Worth LL, Gilbert BE, Knight V.

Clin Cancer Res. 2000 Jul;6(7):2876-80.

35.

A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies.

Jia SF, Worth LL, Kleinerman ES.

Clin Exp Metastasis. 1999;17(6):501-6.

PMID:
10763916
36.

Congenital hepatoblastoma and schizencephaly in an infant with Beckwith-Wiedemann syndrome.

Worth LL, Slopis JM, Herzog CE.

Med Pediatr Oncol. 1999 Dec;33(6):591-3. No abstract available.

PMID:
10573588
37.
38.

Transient leukemia with extreme basophilia in a phenotypically normal infant with blast cells containing a pseudodiploid clone, 46,XY i(21)(q10).

Worth LL, Zipursky A, Christensen H, Tubergen D.

J Pediatr Hematol Oncol. 1999 Jan-Feb;21(1):63-6.

PMID:
10029816
40.

Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma.

Worth LL, Jaffe N, Benjamin RS, Papadopoulos NE, Patel S, Raymond AK, Jia SF, Rodriguez C, Gano J, Gianan MA, Kleinerman ES.

Clin Cancer Res. 1997 Oct;3(10):1721-9.

41.

Multisite phosphorylation of ornithine decarboxylase in transformed macrophages results in increased intracellular enzyme stability and catalytic efficiency.

Reddy SG, Mcllheran SM, Cochran BJ, Worth LL, Bishop LA, Brown PJ, Knutson VP, Haddox MK.

J Biol Chem. 1996 Oct 4;271(40):24945-53.

42.

The organization and expression of the mdm2 gene.

de Oca Luna RM, Tabor AD, Eberspaecher H, Hulboy DL, Worth LL, Colman MS, Finlay CA, Lozano G.

Genomics. 1996 May 1;33(3):352-7.

PMID:
8660994

Supplemental Content

Loading ...
Support Center